Direct and indirect costs of refractory epilepsy in an epilepsy center in Germany;Die direkten und indirekten Kosten therapierefraktärer epilepsie

Neurologie und Rehabilitation

Volumn 14, Issue 3, 2008, Pages 133-140

  Strzelczyk, Adam ^a   Nickolay, T ^a   Reese, J P ^a   Bauer, S ^a   Knake, S ^a   Rosenow, F ^a   Dodel, R ^a   Hamer, H M ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Cost of illness; Direct costs; Epilepsy; Indirect costs

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VIGABATRIN;

ARTICLE; CONTROLLED STUDY; COST OF ILLNESS; DISEASE DURATION; DRUG COST; EPILEPSY; FOCAL EPILEPSY; GERMANY; HEALTH CARE COST; HEALTH CENTER; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT CARE; PHYSIOTHERAPY; QUESTIONNAIRE; RETIREMENT; TERTIARY HEALTH CARE; TONIC CLONIC SEIZURE;

EID: 47849119490     PISSN: 09472177     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J: Cost of disorders of the brain in Europe. Eur J Neurol 2005; 12 Suppl 1: 1-27
2. Beghi E, Garattini L, Ricci E, Cornago D, Parazzini F: Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia 2004; 45: 171-178
3. Begley CE, Annegers JF, Lairson DR, Reynolds TF: Estimating the cost of epilepsy. Epilepsia 1999; 40 Suppl 8: 8-13
4. Begley CE, Annegers JF, Lairson DR, Reynolds TF: Methodological issues in estimating the cost of epilepsy. Epilepsy research 1999; 33: 39-55
5. Begley CE, Annegers JF, Lairson DR, Reynolds TF, Hauser WA: Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 1994; 35: 1230-1243
6. Beran RG: The burden of epilepsy for the patient: the intangible costs. Epilepsia 1999; 40 Suppl 8: 40-43
7. Berto P, Tinuper P, Viaggi S: Cost-of-illness of epilepsy in Italy. Data from a multicentre observational study (Episcreen). PharmacoEconomics 2000; 17: 197-208
8. Blume WT, Luders HO, Mizrahi E, et al.: Glossary of descriptive terminology for ictal semiology: report of the ILAE task force on classification and terminology. Epilepsia 2001; 42: 1212-1218
9. Boon P, D'Have M, Van Walleghem P, et al.: Direct medical costs of refractory epilepsy incurred by three different treatment modalities: a prospective assessment. Epilepsia 2002; 43: 96-102
10. Cockerell OC, Hart YM, Sander JW, Shorvon SD: The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy research 1994; 18: 249-260
11. Dodel R, Rosenow F, Hamer HM: [The costs of epilepsy in Germany]. Pharmazie in unserer Zeit 2007; 36: 298-305
12. Dodel RC, Pepperl S, Kohne-Volland R, et al.: [Costs of drug treatment of neurologic diseases: Parkinson disease, dystonia, epilepsy]. Med Klin (Munich) 1996; 91: 479-485
13. Drummond M: Cost-of-illness studies: a major headache? Pharmaco-Economics 1992; 2: 1-4
14. Drummond M: Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford Univ Press; 2005
15. Forsgren I, Beghi E, Ekman M: Cost of epilepsy in Europe. Eur J Neurol 2005; 12 Suppl 1: 54-58
16. Forsgren L, Beghi E, Oun A, Sillanpaa M: The epidemiology of epilepsy in Europe - a systematic review. Eur J Neurol 2005;12:245-253
17. Fröscher W, Blankenhorn V, May TW. Pharmakotherapie der Epilepsie. Stuttgart: Schattauer; 2000
18. Hamer HM, Spottke A, Aletsee C, et al.: Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany. Epilepsia 2006; 47: 2165-2172
19. Heaney DC, Sander JW, Shorvon SD: Comparing the cost of epilepsy across eight European countries. Epilepsy research 2001; 43: 89-95
20. Jacoby A, Buck D, Baker G, et al.: Uptake and costs of care for epilepsy: findings from a U.K. regional study. Epilepsia 1998; 39: 776-786
21. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L: The friction cost method for measuring indirect costs of disease. Journal of health economics 1995; 14: 171-189
22. Kotsopoulos IA, Evers SM, Ament AJ, de Krom MC: Estimating the costs of epilepsy: an international comparison of epilepsy cost studies. Epilepsia 2001; 42: 634-640
23. Langfitt JT: Cost evaluations in epilepsy: an update. Epilepsia 2000; 41 Suppl 2: S62-68
24. Pfäfflin M, May T, Stefan H, Adelmeier U: Epilepsiebedingte Beeinträchtigungen im täglichen Leben und in der Erwerbstätigkeit - Querschnittsstudie an Patienten niedergelassener Ärzte. Neurol Rehabil 2000; 6: 140-148
25. Schöffski O, v.d. Schulenburg J: Gesundheitsökonomische Evaluationen. 3., vollständig überarb. Aufl. ed. Berlin: Springer; 2007
26. Schwabe U: Antiepileptika. In: Schwabe U, Paffrath D eds, Arzneimittelverordnungsreport. Stuttgart: G. Fischer Verlag; 2006: 394-405
27. Spottke AE, Reuter M, Machat O, et al.: Cost of illness and its predictors for Parkinson's disease in Germany. PharmacoEconomics 2005; 23: 817-836
28. Tetto A, Manzoni P, Millul A, et al.: The costs of epilepsy in Italy: a prospective cost-of-illness study in referral patients with disease of different severity. Epilepsy research 2002; 48: 207-216
29. Thorbecke R, Specht U: Rehabilitation und Berufstätigkeit bei Menschen mit Epilepsie. TW Neurologie Psychiatrie 1993; 7: 283-288
30. van Hout B, Gagnon D, Souetre E, et al.: Relationship between seizure frequency and costs and quality of life of outpatients with partial epilepsy in France, Germany, and the United Kingdom. Epilepsia 1997; 38: 1221-1226